B-Cell Lymphomas

Common Name(s)

B-Cell Lymphomas

Lymphoma is the most common blood cancer. Lymphocytes are a type of white blood cell that are part of our body’s immune system and help our body fight infections. Lymphoma occurs when these lymphocytes grow and multiply uncontrollably. The body has two main types of lymphocytes, B-lymphocytes (B-cells) and T-lymphocytes (T-cells). B-cell lymphoma occurs when the B-cells in particular grow into lymphomas. The cancerous lymphocyte cells can then travel to various parts of the body including the lymph nodes, blood, spleen, bone marrow and other organs. There are many different types of B-cell lymphomas and the most common type is called diffuse large b-cell lymphoma (DLBCL) which is aggressive (fast-growing) and requires immediate treatment. There are other forms that are slow-growing and respond well to treatment and can go into remission for many years. Genetic factors as well as environmental factors, weak immune system (immunodeficiency due to an organ transplant or HIV/AIDS), drug and chemical exposures, viruses and other unknown factors are thought to play a role in the development of lymphoma.

Symptoms are variable but can include: swollen lymph glands, fevers, night sweats, fatigue, unexplained weight loss, pain or abdominal bloating, chest pain, cough, difficulty breathing. Diagnosis may include physical exam of the lymph nodes, spleen and liver, blood tests, x-rays, scans, and finally a biopsy from lymph tissue. The treatment and prognosis or outlook depends upon the specific type of B-cell lymphoma and other factors present but often includes radiation, chemotherapy and medications. Speak with your physician for the most current treatment options. Support groups are also a great resource for support and information and can help connect you to other individuals with B-cell lymphoma.

Source: Advocacy organizations associated with the condition.

 

Advocacy and Support Organizations

 

Condition Specific Organizations

Following organizations serve the condition "B-Cell Lymphomas" for support, advocacy or research.

There are currently no organizations listed in Disease InfoSearch that support this condition. Create a listing.

 

 

General Support Organizations

Not finding the support you need? Show General Support Organizations

 
 
Top

How do you compare to others with this condition?

Privately answer questions about your health. Let resources, you select, come to you.

Anonymously share and see how your answers compare with others with this condition while privately providing key pieces of information to medical researchers, disease advocacy groups, and others ONLY YOU select to help speed up cures and better alternatives.

 
 

Advocacy and Support Organizations

 

Condition Specific Organizations

Following organizations serve the condition "B-Cell Lymphomas" for support, advocacy or research.

There are currently no organizations listed in Disease InfoSearch that support this condition. Create a listing.

 

 

General Support Organizations

Not finding the support you need? Show General Support Organizations

 
 
 
 
Top

Scientific Literature

Articles from the PubMed Database

Research articles describe the outcome of a single study. They are the published results of original research.
The terms "B-Cell Lymphomas" returned 556 free, full-text research articles on human participants. First 3 results:

Investigation of potential traces of pluripotency in germinal-center-derived B-cell lymphomas driven by MYC.
 

Author(s): R Wagener, M Lenz, B Schuldt, I Lenz, A Schuppert, R Siebert, F-J Müller

Journal:

 

Last Updated: 30 May 2015

Go To URL
Protein kinase CK2 is widely expressed in follicular, Burkitt and diffuse large B-cell lymphomas and propels malignant B-cell growth.
 

Author(s): Marco Pizzi, Francesco Piazza, Claudio Agostinelli, Fabio Fuligni, Pietro Benvenuti, Elisa Mandato, Alessandro Casellato, Massimo Rugge, Gianpietro Semenzato, Stefano A Pileri

Journal: Oncotarget. 2015 Mar;6(9):6544-52.

 

Serine-threonine kinase CK2 is highly expressed and pivotal for survival and proliferation in multiple myeloma, chronic lymphocytic leukemia and mantle cell lymphoma. Here, we investigated the expression of α catalytic and β regulatory CK2 subunits by immunohistochemistry in 57 ...

Last Updated: 21 Apr 2015

Go To URL
Somatic mutations of cell-free circulating DNA detected by next-generation sequencing reflect the genetic changes in both germinal center B-cell-like and activated B-cell-like diffuse large B-cell lymphomas at the time of diagnosis.
 

Author(s): Elodie Bohers, Pierre Julien Viailly, Sydney Dubois, Philippe Bertrand, Catherine Maingonnat, Sylvain Mareschal, Philippe Ruminy, Jean-Michel Picquenot, Christian Bastard, Fabienne Desmots, Thierry Fest, Karen Leroy, Hervé Tilly, Fabrice Jardin

Journal: Haematologica. 2015 Jul;100(7):e280-4.

 

Last Updated: 1 Jul 2015

Go To URL

Reviews from the PubMed Database

Review articles summarize what is currently known about a disease. They discuss research previously published by others.
The terms "B-Cell Lymphomas" returned 43 free, full-text review articles on human participants. First 3 results:

Mutation of chromatin modifiers; an emerging hallmark of germinal center B-cell lymphomas.
 

Author(s): M A Lunning, M R Green

Journal:

 

Subtypes of non-Hodgkin's lymphomas align with different stages of B-cell development. Germinal center B-cell (GCB)-like diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL) and Burkitt's lymphoma (BL) each share molecular similarities with normal GCB cells. Recent next-generation ...

Last Updated: 17 Oct 2015

Go To URL
Double hit diffuse large B-cell lymphomas: diagnostic and therapeutic challenges.
 

Author(s): Jonathan W Friedberg

Journal: Chin Clin Oncol. 2015 Mar;4(1):9.

 

Although diffuse large B-cell lymphoma (DLBCL) is curable with standard chemoimmunotherapy, over 30% of patients with advanced stage disease experience refractory disease or progression. Recent studies suggest that rearrangement of the myc oncogene occurs in approximately 10% of patients ...

Last Updated: 6 Apr 2015

Go To URL
Hepatitis C virus-associated B-cell non-Hodgkin lymphomas.
 

Author(s): Barbara Vannata, Emanuele Zucca

Journal: Hematology Am Soc Hematol Educ Program. 2014 Dec;2014(1):590-8.

 

Epidemiological studies have demonstrated an increased risk of developing B-cell lymphomas in patients with chronic hepatitis C virus (HCV) infection. However, the strength of the association shows great geographic discrepancies, with higher relative risk in countries with high HCV ...

Last Updated: 20 Feb 2015

Go To URL
 
 
Top

Symptoms, Diagnosis, and Treatment

There are currently no related results available in GeneReviews.

There are currently no related results available in Genetic Testing Registry.

 
 
Top

Clinical Trial Information This information is provided by ClinicalTrials.gov

Study of BKM120 & Rituximab in Patients With Relapsed or Refractory Indolent B-Cell Lymphoma
 

Status: Recruiting

Condition Summary: Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue; Nodal Marginal Zone B-cell Lymphoma; Recurrent Grade 1 Follicular Lymphoma; Recurrent Grade 2 Follicular Lymphoma; Recurrent Grade 3 Follicular Lymphoma; Recurrent Mantle Cell Lymphoma; Recurrent Marginal Zone Lymphoma; Splenic Marginal Zone Lymphoma; Waldenström Macroglobulinemia

 

Last Updated: 20 Oct 2015

Go to URL
Ibrutinib and Lenalidomide With Dose Adjusted EPOCH-R in Subjects With Relapsed/Refractory Diffuse Large B-cell Lymphoma
 

Status: Recruiting

Condition Summary: Diffuse Large B Cell Lymphoma Relapsed; Diffuse Large B Cell Lymphoma Refractory

 

Last Updated: 2 Sep 2015

Go to URL
Lenalidomide and Combination Chemotherapy (DA-EPOCH-R) in Treating Patients With MYC-Associated B-Cell Lymphomas
 

Status: Recruiting

Condition Summary: Adult Grade III Lymphomatoid Granulomatosis; B-cell Chronic Lymphocytic Leukemia; Contiguous Stage II Adult Diffuse Large Cell Lymphoma; Contiguous Stage II Adult Diffuse Mixed Cell Lymphoma; Contiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma; Contiguous Stage II Adult Immunoblastic Large Cell Lymphoma; Contiguous Stage II Grade 1 Follicular Lymphoma; Contiguous Stage II Grade 2 Follicular Lymphoma; Contiguous Stage II Grade 3 Follicular Lymphoma; Contiguous Stage II Mantle Cell Lymphoma; Contiguous Stage II Marginal Zone Lymphoma; Contiguous Stage II Small Lymphocytic Lymphoma; Cutaneous B-cell Non-Hodgkin Lymphoma; Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue; Intraocular Lymphoma; Nodal Marginal Zone B-cell Lymphoma; Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma; Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma; Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma; Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma; Noncontiguous Stage II Grade 1 Follicular Lymphoma; Noncontiguous Stage II Grade 2 Follicular Lymphoma; Noncontiguous Stage II Grade 3 Follicular Lymphoma; Noncontiguous Stage II Mantle Cell Lymphoma; Noncontiguous Stage II Marginal Zone Lymphoma; Noncontiguous Stage II Small Lymphocytic Lymphoma; Progressive Hairy Cell Leukemia, Initial Treatment; Small Intestine Lymphoma; Splenic Marginal Zone Lymphoma; Stage 0 Chronic Lymphocytic Leukemia; Stage I Adult Diffuse Large Cell Lymphoma; Stage I Adult Diffuse Mixed Cell Lymphoma; Stage I Adult Diffuse Small Cleaved Cell Lymphoma; Stage I Adult Hodgkin Lymphoma; Stage I Adult Immunoblastic Large Cell Lymphoma; Stage I Chronic Lymphocytic Leukemia; Stage I Grade 1 Follicular Lymphoma; Stage I Grade 2 Follicular Lymphoma; Stage I Grade 3 Follicular Lymphoma; Stage I Mantle Cell Lymphoma; Stage I Marginal Zone Lymphoma; Stage I Small Lymphocytic Lymphoma; Stage II Adult Hodgkin Lymphoma; Stage II Chronic Lymphocytic Leukemia; Stage II Small Lymphocytic Lymphoma; Stage III Adult Diffuse Large Cell Lymphoma; Stage III Adult Diffuse Mixed Cell Lymphoma; Stage III Adult Diffuse Small Cleaved Cell Lymphoma; Stage III Adult Hodgkin Lymphoma; Stage III Adult Immunoblastic Large Cell Lymphoma; Stage III Chronic Lymphocytic Leukemia; Stage III Grade 1 Follicular Lymphoma; Stage III Grade 2 Follicular Lymphoma; Stage III Grade 3 Follicular Lymphoma; Stage III Mantle Cell Lymphoma; Stage III Marginal Zone Lymphoma; Stage III Small Lymphocytic Lymphoma; Stage IV Adult Diffuse Large Cell Lymphoma; Stage IV Adult Diffuse Mixed Cell Lymphoma; Stage IV Adult Diffuse Small Cleaved Cell Lymphoma; Stage IV Adult Hodgkin Lymphoma; Stage IV Adult Immunoblastic Large Cell Lymphoma; Stage IV Chronic Lymphocytic Leukemia; Stage IV Grade 1 Follicular Lymphoma; Stage IV Grade 2 Follicular Lymphoma; Stage IV Grade 3 Follicular Lymphoma; Stage IV Mantle Cell Lymphoma; Stage IV Marginal Zone Lymphoma; Stage IV Small Lymphocytic Lymphoma; Testicular Lymphoma; Untreated Hairy Cell Leukemia; Waldenström Macroglobulinemia

 

Last Updated: 9 Sep 2015

Go to URL